Onesource Specialty Pharma Intrinsic Value
Onesource Specialty Pharma (ONESOURCE) median intrinsic value is ₹472.80 from 7 valuation models (range ₹473–₹3940), vs current price ₹1576.00 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse ONESOURCE shareholder distribution to track promoter, FII and institutional holdings.
ONESOURCE Valuation Methods Summary — DCF, Graham Number & P/E
Onesource Specialty Pharma intrinsic value across 7 models vs current price ₹1576.00 — upside/downside and value range per method. For current market price and key ratios, visit ONESOURCE share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹472.80 | ₹378.24 - ₹567.36 | -70.0% | EPS: ₹1.60, Sector P/E: 22x |
| Book Value Method | asset | ₹3940.00 | ₹3546.00 - ₹4334.00 | +150.0% | Book Value/Share: ₹4859.17, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2866.67 | ₹2580.00 - ₹3153.34 | +81.9% | Revenue/Share: ₹1433.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3133.33 | ₹2820.00 - ₹3446.66 | +98.8% | EBITDA: ₹376.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹472.80 | ₹425.52 - ₹520.08 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹472.80 | ₹425.52 - ₹520.08 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹472.80 | ₹425.52 - ₹520.08 | -70.0% | EPS: ₹1.60, BVPS: ₹4859.17 |
ONESOURCE Intrinsic Value vs Market Price — All Valuation Models
Onesource Specialty Pharma fair value range ₹473–₹3940 vs current market price ₹1576.00 across 7 valuation models. Read Onesource Specialty Pharma dividend policy for the complete payout history and dividend yield track record.
ONESOURCE Intrinsic Value Analysis — Undervalued or Overvalued?
Onesource Specialty Pharma median intrinsic value ₹472.80, current price ₹1576.00 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of ONESOURCE?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Onesource Specialty Pharma (ONESOURCE) is ₹472.80 (median value). With the current market price of ₹1576.00, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹472.80 to ₹3940.00, indicating ₹472.80 - ₹3940.00.
Is ONESOURCE undervalued or overvalued?
Based on our multi-method analysis, Onesource Specialty Pharma (ONESOURCE) appears to be trading above calculated value by approximately 70.0%.
ONESOURCE Financial Health — Key Ratios vs Industry Benchmarks
Onesource Specialty Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.52 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 0.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.21x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ONESOURCE Cash Flow Quality — Operating & Free Cash Flow
Onesource Specialty Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-68 Cr | ₹-169 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-107 Cr | ₹-107 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-163 Cr | ₹-197 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-416 Cr | ₹-762 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-118 Cr | ₹-222 Cr | Negative Cash Flow | 3/10 |